LipoScience Collaborates with a Leading Academic Medical Center to Identify Risk Factors Aimed at Improving Management of Acute Coronary Syndrome

RALEIGH, N.C.--(BUSINESS WIRE)--LipoScience, Inc., an in vitro diagnostic company committed to advancing patient care in cardiovascular, metabolic and other diseases, today announced that it has entered into a research agreement with Duke University School of Medicine. The research will be aimed at identifying cardiovascular risk factors that can be used alone or in combination with other clinical measures to improve stratification and management of acute coronary syndrome. The agreement encompasses studies to be performed with Duke’s CATHGEN (CATHeterizationGENetics) and other patient registries.

“We look forward to working with the Duke team to identify new disease markers in the acute coronary syndrome population.”

Under the terms of the agreement, LipoScience will perform NMR LipoProfile^® test analysis and other metabolite assays of blood samples from the registries to learn more about the relationship between lipoproteins and acute coronary syndrome in these patient populations.

“Currently available clinical diagnostic tests provide imprecise measures of cardiovascular risk, particularly with respect to acute coronary events. Also, functional studies are similarly relatively imprecise with respect to diagnostic information regarding moderately severe coronary artery disease. Development of ancillary and complementary information is of prime interest in clinical cardiology,” said William E. Kraus, M.D., Professor of Medicine at Duke University Medical Center. “The purpose of this research is to investigate how cardiovascular risk genes, biochemical markers, and currently available cardiovascular functional studies improve the way cardiovascular disease is diagnosed, predicted and managed.”

“Through this collaboration, LipoScience will gain access to a large patient registry and will work with leading researchers in the field to investigate the clinical utility of the NMR LipoProfile test,” said Ray Pourfarzib, Ph.D., Vice President, Medical Affairs at LipoScience. “We look forward to working with the Duke team to identify new disease markers in the acute coronary syndrome population.”

The CATHGEN registry was collected between 2001 and 2011 to create a significant combined biochemical and clinical bio- and data repositories for cardiovascular disease research. The data repository contains genetic information, blood biochemical marker data, clinical information and clinical endpoint follow-up.

About LipoScience, Inc.

LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. Its first proprietary diagnostic test, the NMR LipoProfile^® test, measures the number of low density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 8 million NMR LipoProfile tests have been ordered. LipoScience’s automated clinical analyzer, Vantera has been cleared by the FDA and will be placed with national and regional clinical laboratories. LipoScience is driving toward a clinical standard of care by decentralizing its technology and expanding its menu of personalized diagnostic tests to address a broad range of metabolic and other diseases. For further information on LipoScience, please visit www.liposcience.com and www.theparticletest.com.